SCIENCE SOURCED WORLDWIDE
LianBio collaborates with world class partners, selecting programs with strong scientific basis and clinical data resulting in a broad and validated late-stage pipeline with first-in-class profile as well as other high potential candidates
Global Clinical Trials Status
Cardiovascular
Phase 1
Phase 2
Phase 3/Pivotal
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Non-obstructive Hypertrophic Cardiomyopathy (nHCM)
Precision Diastolic Disease (HFpEF)
Oncology
Phase 1
Phase 2
Phase 3/Pivotal
Head and Neck Cancer
Solid tumor IO combinations
First-line Cholangiocarcinoma (1LCCA)
Second-line Cholangiocarcinoma (2LCCA)*
Gastric Cancer and Other FGFR-Driven Tumors
*LianBio will pursue approval in ex-China LianBio Territories via CPP (i.e. clinical trial waivers with regulatory submission post US FDA approval).
SHP2 Inhibitor for RTK Cancers
Ophthalmology
Phase 1
Phase 2
Phase 3/Pivotal
Demodex blepharitis
Meibomian gland disease
Inflammatory Disease
Phase 1
Phase 2
Phase 3/Pivotal
Ulcerative Colitis
Crohn’s Disease
Ulcerative Colitis
Crohn’s Disease
Chronic Rhinosinusitis (CRS)
